Pfizer (NYSE:PFE) announced on Tuesday that it plans to sell approximately 700 million shares of common stock in Haleon (NYSE:HLN) to reduce its stake in the British consumer healthcare giant from about 15.0% to 7.3%, which would mean divesting about 7.7% of its outstanding shares.